New pathogenic and therapeutic paradigms in atopic dermatitis |
| |
Affiliation: | 1. Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai Medical School, New York, NY, United States;2. Columbia University, College of Physicians and Surgeons, New York, NY, United States;1. Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran, Iran;2. Stem Cell Technology Research Center, Tehran, Iran;1. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY;3. Translational Technology Core Laboratory, Rockefeller University, New York, NY;2. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY;7. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY;8. Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY;4. Columbia University College of Physicians and Surgeons, New York, NY;5. Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill;6. Department of Dermatology, Tel-Hashomer Hospital, Tel Aviv, Israel;1. Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA;2. Departments of Dermatology and Pathology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA;1. Department of Dermatology, Eberhard Karls University, Tübingen, Germany;2. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland;3. Department of Dermatology and Allergy Biederstein, Technische Universität München, Munich, Germany;1. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY;2. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY |
| |
Abstract: | Atopic Dermatitis (AD) is a common inflammatory skin disease with increasing prevalence in industrialized countries. Up to one-third of adults with AD have moderate-to-severe disease, leading to a large, unmet need for effective treatments. While current therapeutics focus mainly on symptom control, major advances have been made in translational research, with the goal of developing drugs to eradicate disease.A translational revolution is now occurring in AD, similar to the one that has occurred in psoriasis over the past decade. Research has focused on elucidating immune pathways responsible for AD, including Th2, Th22, and Th17 pathways, with testing of immune antagonists specific to these axes. An IL-4R antagonist, dupilumab, is the first drug that shows great promise in phase II trials. By studying clinical and molecular responses following treatment with specific immune antagonists, our understanding of and ability to treat AD will expand. |
| |
Keywords: | Atopic dermatitis Translational medicine T-cells Immune antagonists |
本文献已被 ScienceDirect 等数据库收录! |
|